Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients
Recruiting
- Conditions
- COVID-19 Convalescent Plasma Treatment
- Registration Number
- NCT05905380
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more selected patients , in particular immunocompromised patients suggest a benefit in these patients whose clinical manifestation seems essentially related to the uncontrolled infection and not the cytokine storm.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Retrospective analysis of the tolerance of Covid-19 convalescent plasma and monoclonal antibodies in the treatment of SARS-Cov2 infections in immunocompromised patients Files analysed retrospectively from February 25, 2020 to January 15, 2023 will be examined This is a retrospective study on patient data from medical records from February 25, 2020 to January 15, 2023
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
🇫🇷Strasbourg, France